Filtered By:
Source: Journal of the American College of Cardiology
Condition: Cholesterol
This page shows you your search results in order of date.
Order by Relevance | Date
Total 24 results found since Jan 2013.
Reply Adding Ezetimibe to Simvastatin for the Secondary Prevention of Cardiovascular Disease: Is it Useful?
In response to Drs. Mascitelli and Goldstein, we previously reported in the primary publication of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) that there was no difference between ezetimibe plus simvastatin as compared with simvastatin alone with respect to cardiovascular death or all-cause mortality (1). Because the focus of the present paper is total cardiovascular events (2), we did not re-report all-cause mortality because the data were previously published, and a subject can only die once. This lack of difference was expected in IMPROVE-IT because prior trials of intensive-dose ve...
Source: Journal of the American College of Cardiology - June 21, 2016 Category: Cardiology Source Type: research
Beyond Coronary Calcification, Family History, and C-Reactive Protein Cholesterol Efflux Capacity and Cardiovascular Risk Prediction
ConclusionsCEC improves ASCVD risk prediction beyond using CAC, FH, and hs-CRP and warrants consideration as a novel ASCVD risk marker.
Source: Journal of the American College of Cardiology - May 24, 2016 Category: Cardiology Source Type: research
Poor Adherence to Statin and Antihypertensive Therapies as Risk Factors for Fatal Stroke
ConclusionsIndividuals with hypercholesterolemia and hypertension who fail to take their prescribed statin and antihypertensive medication experience a substantially increased risk of fatal stroke. The risk is lower if the patient is adherent to either one of these therapies.
Source: Journal of the American College of Cardiology - March 29, 2016 Category: Cardiology Source Type: research
Adherence to Medical Therapy and the Global Burden of Cardiovascular Disease ∗
Ischemic heart disease and cerebrovascular disease account for>20% of worldwide mortality and are the 2 leading causes of death on a global basis (1). Although mortality from ischemic heart disease is greater than that from stroke worldwide, the mortality from stroke is actually higher than from ischemic heart disease in 39% of countries. For example, mortality from stroke is generally higher than that for ischemic heart disease in China, Africa, and South America. In addition, stroke disability–adjusted life-year loss rates exceed ischemic heart disease-related disability in 32% of countries (2). Because of this, strate...
Source: Journal of the American College of Cardiology - March 29, 2016 Category: Cardiology Source Type: research
Utility of Nontraditional Risk Markers in Atherosclerotic Cardiovascular Disease Risk Assessment
ConclusionsCAC score, ABI, and FH were independent predictors of ASCVD events. CAC score modestly improved the discriminative ability of the cPCE compared with other nontraditional risk markers.
Source: Journal of the American College of Cardiology - January 12, 2016 Category: Cardiology Source Type: research
Selecting Patients for Statin Therapy in Primary Prevention If We Could Only Predict the Future ∗
Statins are effective in the primary and secondary prevention of coronary heart disease and stroke. Although many would agree that primary prevention of atherosclerotic cardiovascular disease (ASCVD) is preferable to secondary prevention, no consensus exists on how to best identify individuals at risk for the disease, when to commence screening and risk assessment, at what age to start (or stop) treatment, how to treat, and how intensively to treat. The 2013 American College of Cardiology/American Heart Association (ACC/AHA) cholesterol guidelines concluded that net benefit was sufficient to recommend statin treatment for ...
Source: Journal of the American College of Cardiology - December 14, 2015 Category: Cardiology Source Type: research
Treatment of Dyslipidemia in Elderly Patients With Coronary Heart Disease There Are Miles to Go Before We Sleep ∗
The treatment of dyslipidemia with statin therapy is a cornerstone in the management of patients in both the primary and secondary prevention settings. Dyslipidemia is widely prevalent in its various forms (1). The lowering of low-density lipoprotein cholesterol (LDL-C) with a statin in patients with established coronary heart disease (CHD) has shown unequivocal capacity to safely reduce risk for clinical sequelae such as nonfatal myocardial infarction, ischemic stroke, cardiovascular and all-cause mortality, as well as the need for revascularization (2,3). The American College of Cardiology/American Heart Association Guid...
Source: Journal of the American College of Cardiology - October 19, 2015 Category: Cardiology Source Type: research
Next Steps in Primary Prevention of Coronary Heart Disease Rationale for and Design of the ECAD Trial
Atherosclerotic cardiovascular disease (ASCVD) events, including coronary heart disease and stroke, are the most frequent cause of death and major disability in the world. Current American College of Cardiology/American Heart Association primary prevention guidelines are mainly on the basis of randomized controlled trials of statin-based low-density lipoprotein cholesterol (LDL-C)–lowering therapy for primary prevention of ASCVD events. Despite the clear demonstration of statin-based LDL-C lowering, substantial 10-year and lifetime risks of incident ASCVD continue. Although the 10-year risk is low in young and middle-age...
Source: Journal of the American College of Cardiology - October 12, 2015 Category: Cardiology Source Type: research
Coronary Calcium Score and the New Guidelines Back to Square One? ∗
Previous guidelines for cardiovascular risk assessment recommended the use of a modified Framingham score to estimate the 10-year risk of hard coronary heart disease (CHD) events, defined as myocardial infarction and CHD death (1). Coronary artery calcium (CAC) scoring for refined stratification received Class IIa or IIb recommendations for those at intermediate (10% to 20%) or low to intermediate (6% to 10%) risk, respectively (2). In 2013, the American College of Cardiology (ACC) and American Heart Association (AHA) released guidelines (3,4) endorsing new sex- and race-specific predictive equations derived from 5 large p...
Source: Journal of the American College of Cardiology - October 5, 2015 Category: Cardiology Source Type: research
Relationship of Oxidized Phospholipids on Apolipoprotein B-100 to Cardiovascular Outcomes in Patients Treated With Intensive Versus Moderate Atorvastatin Therapy The TNT Trial
ConclusionsElevated OxPL-apoB levels predict secondary MACE in patients with stable CHD, a risk that is mitigated by atorvastatin 80 mg. (A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels [TNT]; NCT00327691)
Source: Journal of the American College of Cardiology - March 30, 2015 Category: Cardiology Source Type: research
Alice in Lipidland The 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol ∗
In the topsy-turvy world of Lewis Carroll’s Alice in Wonderland(1), the Cheshire Cat said, “only a few find the way, some don’t recognize it when they do—some … don’t ever want to.” Such was the status of many healthcare providers and patients in November 2013 at the issuance of the 2013 American College of Cardiology/American Heart Association Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults (2). This was coupled with the Guideline on the Assessment of Cardiovascular Risk (3), using a new risk assessment calculator, the Pooled Cohort Equations (4), to es...
Source: Journal of the American College of Cardiology - November 24, 2014 Category: Cardiology Source Type: research
Heart Failure With Preserved Ejection Fraction: Comparison of Patients With and Without Angina Pectoris (From the Duke Databank for Cardiovascular Disease)
This study investigated the characteristics and outcomes of patients with heart failure with preserved ejection fraction (HFpEF) and angina pectoris (AP).Background: AP is a predictor of adverse events in patients with heart failure with reduced EF. The implications of AP in HFpEF are unknown.Methods: We analyzed HFpEF patients (EF ≥50%) who underwent coronary angiography at Duke University Medical Center from 2000 through 2010 with and without AP in the previous 6 weeks. Time to first event was examined using Kaplan-Meier methods for the primary endpoint of death/myocardial infarction (MI)/revascularization/stroke (...
Source: Journal of the American College of Cardiology - October 25, 2013 Category: Cardiology Authors: Robert J. Mentz, Samuel Broderick, Linda K. Shaw, Mona Fiuzat, Christopher M. O'Connor Tags: Heart Failure Source Type: research
Early High-Dose Rosuvastatin for Contrast-Induced Nephropathy Prevention in Acute Coronary Syndrome: Results From the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On Contrast-Induced Acute Kidney Injury and Myocardial Damage in Patients With Acute Coronary Syndrome)
Conclusions: High-dose rosuvastatin given on admission to statin-naïve patients with ACS who are scheduled for an early invasive procedure can prevent CI-AKI and improve short-term clinical outcome. (Statin Contrast Induced Nephropathy Prevention [PRATO-ACS]; NCT01185938)
Source: Journal of the American College of Cardiology - September 27, 2013 Category: Cardiology Authors: Mario Leoncini, Anna Toso, Mauro Maioli, Francesco Tropeano, Simona Villani, Francesco Bellandi Tags: Cardiac Imaging Source Type: research
Benefits of Statins in Elderly Subjects Without Established Cardiovascular Disease: A Meta-Analysis
Conclusions: In elderly subjects at high CV risk without established CV disease, statins significantly reduce the incidence of MI and stroke, but do not significantly prolong survival in the short-term.
Source: Journal of the American College of Cardiology - August 16, 2013 Category: Cardiology Authors: Gianluigi Savarese, Antonio M. Gotto, Stefania Paolillo, Carmen D'Amore, Teresa Losco, Francesca Musella, Oriana Scala, Caterina Marciano, Donatella Ruggiero, Fabio Marsico, Giuseppe De Luca, Bruno Trimarco, Pasquale Perrone-Filardi Tags: Cardiometabolic Risk Source Type: research
Low High-Density Lipoprotein Cholesterol Is Not a Risk Factor for Recurrent Vascular Events in Patients With Vascular Disease on Intensive Lipid-Lowering Medication
Conclusions: In patients with clinically manifest vascular disease using no or usual dose lipid-lowering medication, low plasma HDL-C levels are related to increased vascular risk, whereas in patients using intensive lipid-lowering medication, HDL-C levels are not related to vascular risk.
Source: Journal of the American College of Cardiology - August 14, 2013 Category: Cardiology Authors: Anton P. van de Woestijne, Yolanda van der Graaf, An-Ho Liem, Maarten J.M. Cramer, Jan Westerink, Frank L.J. Visseren, SMART Study Group Tags: Cardiometabolic Risk Source Type: research
